Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

4.5K
A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K
Adult Stem Cells01:33

Adult Stem Cells

33.9K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.9K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.5K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.5K
Embryonic Stem Cells00:57

Embryonic Stem Cells

5.1K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
5.1K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Experimental and Computational Profiling of Curcumin-Derived Diarylpentanoids Reveals Mechanistic Determinants of COX1/COX2 Inhibition and Selectivity.

ACS omega·2026
Same author

Receptor-Selective Modulation of Cannabinoid Signaling by Cardamonin: Integrating Molecular Dynamics, Free Energy Calculations, and Behavioral Validation.

ACS omega·2026
Same author

Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways.

Investigative ophthalmology & visual science·2026
Same author

Expression of concern: Evaluating the biological characteristics of targeted ZIF-8-encapsulated individual and combined drug systems for enhanced <i>in vivo</i> toxicity mitigation using folic acid ligands.

RSC advances·2026
Same author

Dose dependent paradoxical increases in DNA methylation, reductions in p16 expression, and changes in histone modifications in gastric cancer cells treated with DNMT inhibitors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Epigenetic regulation of autophagy in cancer: A double-edged sword in tumor progression and therapy resistance.

International review of cell and molecular biology·2026

Related Experiment Video

Updated: Feb 8, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.8K

CD133: beyond a cancer stem cell biomarker.

Amir Barzegar Behrooz1, Amir Syahir1, Syahida Ahmad1

  • 1a Department of Biochemistry, Faculty of Biotechnology and Biomolecular Science , Universiti Putra Malaysia , Serdang , Malaysia.

Journal of Drug Targeting
|June 19, 2018
PubMed
Summary

CD133, a key cancer stem cell marker, drives tumor growth, metastasis, and drug resistance. Inhibiting CD133 offers a potential therapeutic strategy by disrupting critical cancer cell signaling pathways.

Keywords:
CD133PI3K-AktWntapoptosisautophagynitric oxide

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

22.8K

Related Experiment Videos

Last Updated: Feb 8, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.8K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

22.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • CD133 (prominin-1) is a crucial biomarker for isolating cancer stem cells (CSCs).
  • CSCs contribute significantly to tumor recurrence and resistance to therapies.
  • CD133 expression is linked to tumor progression, metastasis, and chemoresistance.

Purpose of the Study:

  • To review the fundamental cell biology of CD133.
  • To discuss CD133's role in cancer stem cell (CSC) biology, including tumorigenesis, metastasis, and drug resistance.
  • To explore CD133 as a potential therapeutic target.

Main Methods:

  • Literature review of studies on CD133 function and signaling pathways.
  • Analysis of CD133's interactions with Wnt/β-catenin and PI3K-Akt pathways.
  • Examination of CD133's influence on apoptosis, angiogenesis, and autophagy.

Main Results:

  • CD133 promotes CSC tumorigenesis, metastasis, and chemoresistance.
  • CD133 interacts with Wnt/β-catenin and PI3K-Akt signaling pathways.
  • CD133 upregulates FLIP, inhibiting apoptosis and promoting angiogenesis via VEGF-A and IL-8.

Conclusions:

  • CD133 is a critical regulator of CSC functions and a potential therapeutic target.
  • Inhibiting CD133 can disrupt key signaling pathways involved in cancer cell proliferation and survival.
  • Understanding CD133's molecular biology is vital for developing novel cancer therapies.